Aurobindo Pharma announced that its wholly owned subsidiary company Eugia Pharma Specialties has received a final approval from the US Food Drug Administration USFDA to manufacture and market Bortezomib for injection 35 mg Bortezomib for Injection 35 mgvial Single-Dose Vial to be bioequivalent and therapeutically equivalent to the Velcade for Injection 35 mgvial of Takeda Pharmaceuticals USA Inc The product is being launched immediately The approved product has a market size of US$ 1172 million for the twelve months ending March 2022 according to IQVIA Bortezomib for injection is indicated for the treatment of Adult patients with multiple myeloma cancer of plasma cells Also used to treat adult patients with mantle cell lymphoma cancer of lymph nodes
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
